Indo-Bangla Pharmaceuticals Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Indo-Bangla Pharmaceuticals's earnings have been declining at an average annual rate of -71.8%, while the Pharmaceuticals industry saw earnings growing at 2.2% annually. Revenues have been declining at an average rate of 37.4% per year.
Key information
-71.75%
Earnings growth rate
-71.89%
EPS growth rate
Pharmaceuticals Industry Growth
11.00%
Revenue growth rate
-37.35%
Return on equity
-1.76%
Net Margin
-11.59%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indo-Bangla Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DSE:IBP Revenue, expenses and earnings (BDT Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
221
-26
52
0
30 Sep 25
198
-33
49
0
30 Jun 25
184
-37
45
0
31 Mar 25
91
-46
34
0
31 Dec 24
88
-44
34
0
30 Sep 24
119
-45
38
0
30 Jun 24
177
-41
44
0
31 Mar 24
212
-18
32
0
31 Dec 23
296
-8
44
0
30 Sep 23
338
-10
65
0
30 Jun 23
374
8
68
0
31 Mar 23
375
-35
128
0
31 Dec 22
416
-22
124
0
30 Sep 22
447
7
109
0
01 Jul 22
485
25
111
0
31 Mar 22
619
117
92
0
31 Dec 21
654
118
103
0
30 Sep 21
731
135
121
0
01 Jul 21
782
135
140
0
31 Mar 21
788
105
134
0
31 Dec 20
843
137
138
0
30 Sep 20
862
150
135
0
30 Jun 20
866
156
133
0
31 Mar 20
853
186
135
0
31 Dec 19
828
183
132
0
30 Sep 19
790
170
130
0
30 Jun 19
741
155
127
0
31 Mar 19
742
134
115
0
31 Dec 18
695
117
113
0
30 Sep 18
667
102
116
0
30 Jun 18
660
98
115
0
31 Mar 18
641
89
115
0
30 Jun 17
617
88
109
0
31 Mar 17
581
93
101
0
30 Jun 16
445
59
92
0
01 Jul 15
435
60
85
0
Quality Earnings: IBP is currently unprofitable.
Growing Profit Margin: IBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBP is unprofitable, and losses have increased over the past 5 years at a rate of 71.8% per year.
Accelerating Growth: Unable to compare IBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).
Return on Equity
High ROE: IBP has a negative Return on Equity (-1.76%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/11 17:26
End of Day Share Price
2026/05/11 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indo-Bangla Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.